Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
drug2120	Piperacillin-tazobactam Wiki	0.71
drug1290	Hydroxychloroquine + lopinavir/ritonavir Wiki	0.71
drug1442	Interferon-β1a Wiki	0.71
drug2261	Protocolised mechanical ventilation strategy Wiki	0.71
drug1116	Fixed-duration Hydrocortisone Wiki	0.71
drug623	Ceftaroline Wiki	0.71
drug3137	XCEL-UMC-BETA Wiki	0.71
drug2868	Ten-days oseltamivir Wiki	0.71
drug189	Amoxicillin-clavulanate Wiki	0.71
drug1117	Fixed-duration higher dose Hydrocortisone Wiki	0.71
drug1670	Macrolide administered for 3-5 days Wiki	0.71
drug2622	Shock-dependent hydrocortisone Wiki	0.71
drug1113	Five-days oseltamivir Wiki	0.71
drug624	Ceftriaxone Wiki	0.71
drug1671	Macrolide administered for up to 14 days Wiki	0.71
drug1786	Moxifloxacin or Levofloxacin Wiki	0.71
drug2898	Therapeutic anticoagulation Wiki	0.50
drug259	Aspirin Wiki	0.41
drug2562	Sarilumab Wiki	0.32
drug192	Anakinra Wiki	0.27
drug1607	Losartan Wiki	0.25
drug1605	Lopinavir/ritonavir Wiki	0.22
drug3085	Vitamin C Wiki	0.20
drug763	Convalescent plasma Wiki	0.16
drug2928	Tocilizumab Wiki	0.12
drug1284	Hydroxychloroquine Wiki	0.07
drug2122	Placebo Wiki	0.04

Correlated MeSH Terms (5)

	Name (Synonyms)	Correlation
D013577	Syndrome NIH	0.07
D055371	Acute Lung Injury NIH	0.07
D012127	Respiratory Distress Syndrome, Newborn NIH	0.07
D012128	Respiratory Distress Syndrome, Adult NIH	0.06
D011014	Pneumonia NIH	0.04

Correlated HPO Terms (1)

	Name (Synonyms)	Correlation
HP:0002090	Pneumonia HPO	0.04

There are 2 clinical trials

Clinical Trials

1 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.

NCT02735707 Community-acquired Pneumonia, Influenza, COVID-19 Drug: Fixed-duration Hydrocortisone Drug: Shock-dependent hydrocortisone Drug: Ceftriaxone Drug: Moxifloxacin or Levofloxacin Drug: Piperacillin-tazobactam Drug: Ceftaroline Drug: Amoxicillin-clavulanate Drug: Macrolide administered for 3-5 days Drug: Macrolide administered for up to 14 days Drug: Five-days oseltamivir Drug: Ten-days oseltamivir Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine Drug: Hydroxychloroquine + lopinavir/ritonavir Drug: Interferon-β1a Drug: Anakinra Drug: Fixed-duration higher dose Hydrocortisone Drug: Tocilizumab Drug: Sarilumab Drug: Vitamin C Drug: Therapeutic anticoagulation Drug: Simvastatin Drug: Convalescent plasma Other: Protocolised mechanical ventilation strategy

MeSH:Pneumonia

HPO:Pneumonia

Primary Outcomes

Measure: All-cause mortality

Time: Day 90

Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection

Measure: Days alive and not receiving organ support in ICU

Time: Day 21

Secondary Outcomes

Measure: ICU Mortality

Time: Day 90

Measure: ICU length of stay

Time: Day 90

Measure: Hospital length of stay

Time: Day 90

Measure: Ventilator free days

Time: Day 28

Measure: Organ failure free days

Time: Day 28

Measure: All-cause mortality

Time: 6 months

Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)

Measure: Health-related Quality of life assessment

Time: 6 months

Measure: Proportion of intubated patients who receive a tracheostomy

Time: Day 28

Description: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital

Measure: Destination at time of hospital discharge

Time: Free text Day 90

Measure: Readmission to the index ICU during the index hospitalization

Time: Day 90

Measure: World Health Organisation 8-point ordinal scale outcome

Time: Hospital discharge

Other Outcomes

Description: Antibiotic Domain specific outcome

Measure: Occurrence of multi-resistant organism colonisation/infection

Time: Day 90, censored at hospital discharge

Description: Antibiotic Domain specific outcome

Measure: Occurrence clostridium difficile

Time: Day 90, censored at hospital discharge

Description: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.

Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death

Time: Day 90, censored at hospital discharge

Description: Antiviral Domain specific outcome. Only required at selected sites.

Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens

Time: Day 3, up to Day 7

Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint

Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing)

Time: Day 90, censored at hospital discharge

2 Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.